The Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as Predictive Tool in Hospitalised Patients With Community‐Acquired Pneumonia (CAP)
Open Access
- 16 June 2025
- journal article
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 19 (6)
Abstract
Background: Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker elevated in severely ill patients, but its prognostic value in community‐acquired pneumonia (CAP) remains unclear. This study aimed to evaluate suPAR's prognostic role for CAP severity compared to other biomarkers and severity scores.Methods: A total of 204 hospitalised CAP patients were enrolled. C‐reactive protein (CRP), procalcitonin (PCT), suPAR, CURB‐65 and Pneumonia Severity Index (PSI) scores were measured at admission, and patients were followed for 365 days. The primary outcome was the relationship between suPAR levels and CAP severity based on IDSA/ATS guidelines. Secondary outcomes included time to clinical stability (TTCS), length of stay (LOS) and mortality.Results: Among 204 patients, 174 (85%) had non‐severe and 30 (15%) had severe CAP. SuPAR levels were not associated with severe CAP (OR 1.03, 95% CI 0.88–1.21; AUC 0.53). Unlike the PSI and CURB‐65 scores, suPAR did not correlate with TTCS (HR PSI 0.80, HR CURB‐65 0.86), though all three markers were correlated to LOS (AUC suPAR 0.61). Only suPAR was significantly associated with 30‐day mortality (HR 1.51, AUC 0.68).Conclusions: The prognostic value of suPAR for CAP severity is low, and it does not provide additional prognostic benefit over the CURB‐65 or PSI scores in predicting CAP severity. While it has moderate predictive ability for 30‐day mortality, its utility for predicting LOS or TTCS is low.Trial Registration: ClinicalTrials.gov identifier: NCT01964495Keywords
This publication has 30 references indexed in Scilit:
- Prognostic value of procalcitonin in community-acquired pneumoniaEuropean Respiratory Journal, 2010
- Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classesEuropean Respiratory Journal, 2007
- Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumoniaBMC Infectious Diseases, 2007
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2007
- The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortalityClinical Microbiology and Infection, 2004
- Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation studyThorax, 2003
- Causes of Death for Patients With Community-Acquired PneumoniaArchives of internal medicine (1960), 2002
- Guidelines for the Management of Adults with Community-acquired PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Time to Clinical Stability in Patients Hospitalized With Community-Acquired PneumoniaJAMA, 1998
- A Prediction Rule to Identify Low-Risk Patients with Community-Acquired PneumoniaNew England Journal of Medicine, 1997